Company news
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. news in 2025
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.'s news releases, calls and decks from 2025, newest first.
Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics
December 4, 2025
The Annals of Oncology Publishes Results of Phase II Study of Sacituzumab Tirumotecan Monotherapy for Urothelial Carcinoma
November 27, 2025
Correction: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
November 26, 2025
Kelun-Biotech Announces Phase III Trial of Sac-TMT in Combination with KEYTRUDA® (pembrolizumab) as First-Line Treatment for PD-L1-Positive NSCLC Met Primary Endpoint
November 24, 2025
Kelun-Biotech Presented TROP2 ADC Sacituzumab Tirumotecan Results From Multiple Clinical Studies at the 2025 CCHIO Congress
November 9, 2025
Kelun-Biotech Presents Positive Phase 3 Data for Trastuzumab Botidotin Compared to T-DM1 at 2025 ESMO
October 20, 2025
Positive Results from Phase 3 OptiTROP-Lung04 Trial of Sacituzumab Tirumotecan Presented at ESMO Presidential Symposium and Simultaneously Published in NEJM
October 19, 2025
Kelun-Biotech Presents Positive Results of Phase 3 Clinical Study OptiTROP-Breast02 for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer at 2025 ESMO
October 18, 2025
Kelun-Biotech's Core product Trastuzumab Botidotin Approved for Marketing by NMPA for HER2-positive BC
October 17, 2025
Third Indication for Kelun-Biotech's TROP2 ADC Sac-TMT Approved for Marketing by NMPA in EGFRm NSCLC Following Progression on EGFR-TKI Therapy
October 11, 2025
Kelun-Biotech to Present Results from Multiple Clinical Studies at the 2025 ESMO Congress
September 23, 2025
Kelun-Biotech's New Drug Application for Its Novel Next-generation Selective RET Inhibitor A400/EP0031 Accepted for Review by the NMPA for the Treatment of RET-fusion positive NSCLC
September 22, 2025
Nature Medicine Publishes Results of Phase II Study of Sacituzumab Tirumotecan Plus Tagitanlimab as First-Line Therapy for NSCLC
August 19, 2025
Kelun-Biotech announces 2025 interim results
August 18, 2025
Kelun-Biotech's Partner Windward Bio Announces Initiation of a Global Phase 2 Asthma Trial of SKB378/WIN378
July 23, 2025
Kelun-Biotech Announces Breakthrough Therapy Designation Granted for Sacituzumab Tirumotecan (Sac-TMT) in Combination With Tagitanlimab in China for Certain Types of Non-Small Cell Lung Cancer
June 10, 2025
The British Medical Journal Publishes Study Results on Sacituzumab Tirumotecan for Previously Treated EGFR-Mutant Advanced NSCLC
June 6, 2025
Kelun-Biotech Announces Approximately US$250 Million Placement
June 5, 2025
Six Abstracts of Kelun-Biotech's Clinical Studies Published at the 2025 ASCO Annual Meeting
May 23, 2025
Fourth NDA for Kelun-Biotech's TROP2 ADC sacituzumab tirumotecan (sac-TMT) Accepted by the Center for Drug Evaluation
May 21, 2025
Kelun-Biotech to Present Results of Six Clinical Studies at 2025 ASCO Annual Meeting
April 24, 2025